Who is sponsoring NCT06827899?

NCT06827899 is sponsored by The First Affiliated Hospital of Xiamen University.

What condition does NCT06827899 study?

NCT06827899 studies Acute Myeloid Leukemia.

Is NCT06827899 still recruiting?

NCT06827899 is currently recruiting now. Last updated 20 February 2025.

Last reviewed 2025-02-20 · How we verify

NCT06827899

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Veneclax, Chidaniline Combined With Azacitidine Followed by Decitabine + MAG Regimen in the Treatment of Elderly Untreated AML

Recruiting now Phase 2 Last updated 20 February 2025

What this trial tests

Phase 2 trial testing veneclax, chidaniline combined with azacitidine (VCA) followed by decitabine + MAG regimen (D-MAG) in Acute Myeloid Leukemia in 66 participants. Currently enrolling.

Timeline

1 July 2022

Primary endpoint
30 June 2026

30 June 2027

Quick facts

Lead sponsor	The First Affiliated Hospital of Xiamen University
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	66
Start date	1 July 2022
Primary completion	30 June 2026
Estimated completion	30 June 2027
Sites	1 location across China

Drugs / interventions tested

veneclax, chidaniline combined with azacitidine (VCA) followed by decitabine + MAG regimen (D-MAG) — full drug profile →

Conditions studied

Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →

Sponsor

The First Affiliated Hospital of Xiamen University

Who can join

60 and older, any sex, with Acute Myeloid Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A multicenter, prospective, single-arm clinical study of veneclax, chidaniline combined with azacitidine (VCA) followed by decitabine + MAG regimen (D-MAG) in the treatment of elderly untreated acute myeloid leukemia (AML)

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Acute Myeloid Leukemia

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT06782542 — Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for I · Phase 2 · recruiting
NCT07177079 — High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML · Phase 1 · recruiting
NCT07384715 — First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod · Phase 1 · recruiting
NCT07107126 — Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes · Phase 1 · recruiting

Other The First Affiliated Hospital of Xiamen University trials

Trials by the same sponsor.

NCT06875063 — GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL · Phase 1 · recruiting
NCT07486492 — Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer · EARLY_PHASE1 · not yet recruiting
NCT07458906 — DLL3-Targeted PET/CT in Neuroendocrine Carcinoma · NA · recruiting
NCT07137052 — Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinomar · not yet recruiting
NCT07189884 — Pyrotinib Maleate Tablets in Combination With Dalpiciclib Isethionate Tablets and Standard Endocrine Therapy · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06827899 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Xiamen University
Last refreshed: 20 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06827899.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing